| Registry | NCT07090629, acronym EPICAC-RUN |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 126 (Actual) |
| Sponsor | Centre Hospitalier Universitaire de la Réunion (Other); collaborators: Aix Marseille Université, Institut National de la Santé Et de la Recherche Médicale, France, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement |
| Conditions | High Cholesterol, Lipodystrophy, Familial Partial, Diabetes |
| Interventions | Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring (Other) |
| Dates | start 2024-05-06, primary completion 2024-12-29, completion 2025-03-21, first posted 2025-07-29, last updated 2025-07-31 |
| Locations | 1 site in Reunion |
Related Papers Related Patents Related Grants Related Experts
All trials for High Cholesterol All trials for Lipodystrophy, Familial Partial All trials of Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring
The goal of this retrospective study is to see whether patients with familial partial type 2 lipodystrophy, who are at high cardiovascular risk present a higher volume of visceral epicardial adipose tissue than other patients without familial partial lipodystrophy who were assessed for their cardiovascular risk using coronary artery calcification scoring between 2016 and 2024.
Coronary artery calcification and clinical cardiovascular risk scoring are insufficient for patients with Familial Partial Lipodystrophy Part 2 (FPLD2), who often develop cardiovascular events before 40 and are insulin resistant. Epicardial adipose tissue volume could be a new, earlier marker of interest for these patients related to inflammation and atherosclerosis. The investigators retrospectively included high cardiovascular risk patients from 2016 to 2023 who had benefited from coronary artery calcification and clinical risk scoring at the University Hospital of La Réunion with Familial Partial Lipodystrophy Type 2 or controls and paired them for age, sex and body mass index. Epicardial adipose tissue volume was measured on the same tododensitometry as the CAC scoring, using a semi, automated technique that had been validated with deep learning at the Univeristy Hospital of Aix-Marseille.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Familial Partial Lipodystrophy, Type 2 (FPLD) | Other: Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring | Adult patients with a confirmed genetic diagnosis of lipodystrophy | |
| Control group of patients at high cardiovascular risk (CTL) | Other: Epicardial adipose tissue measurement on the available tododensitometry used for coronary calcium scoring | Patients without Familial Partial Lipodystrophy |
Sex: All, ages: 18 Years to any
Inclusion Criteria: Patients who received a check-up for hypercholesterolemia, obesity or diabetes including a CT scan to measure the coronary calcium score at the CHU de La Réunion between 2016 and 2023 Exclusion Criteria: None
| Facility | City | Country | Status |
|---|---|---|---|
| CHU de La Réunion | Saint-Pierre | Reunion |